1 Min Read
Jan 9 (Reuters) - Mylan:
* SAYS ITS BIOSIMILAR FOR AMGEN’S NEULASTA COULD BE A “MID-YEAR OPPORTUNITY”
* SAYS U.S. TAX REFORM RELATIVELY NEUTRAL FOR THE COMPANY Source text for Eikon: Further company coverage: (Reporting By Michael Erman)
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.